Chronic Hepatitis: Metabolic, Cholestatic, Viral and Autoimmune

Name: Chronic Hepatitis: Metabolic, Cholestatic, Viral and Autoimmune
Brand: Springer Nature
SKU: 9781402065224
Availability: InStock

Best Price (Coupon Required):
Buy Chronic Hepatitis: Metabolic, Cholestatic, Viral and Autoimmune for $153.00 at @ Link.springer.com when you apply the 10% OFF coupon at checkout.
Click “Get Coupon & Buy” to copy the code and unlock the deal.

Set a price drop alert to never miss an offer.

1 Offer Price Range: $169.99 - $169.99

BEST PRICE

Single Product Purchase

$153.00

@ Link.springer.com with extra coupon

Price Comparison

Seller	Contact Seller	List Price	On Sale	Shipping	Best Promo	Final Price	Volume Discount	Financing	Availability	Seller's Page
BEST PRICE 1 Product Purchase @ Link.springer.com		$169.99	$169.99		10% OFF This deals requires coupon	$153.00		See Site	In stock	Visit Store

Product Details

Brand

Springer Nature

Manufacturer

N/A

Part Number

GTIN

9781402065224

Condition

New

Product Description

This book is the proceedings of Falk Symposium 157, entitled Chronic Hepatitis: Metabolic, Cholestatic, Viral and Autoimmune, held in Freiburg, Germany, on 10--11 October 2006 (one of three symposia during the XIII Falk Liver Week 2006). It provides up-to-date information on new developments in the field of chronic hepatitis and its various entities. In recent decades we have learned how heterogeneous the clinical entity of chronic hepatitis has become. The liver, as the central organ of metabolism and detoxification, is more than ever a target of disease processes evolving from the spread of obesity in the western world. Apart from nonalcoholic steatohepatitis (NASH), alcoholic liver disease is still the most prevalent liver disease in the west. Alcohol-induced liver disease exhibits a broad clinical spectrum from alcoholic steatohepatitis to cirrhosis. Alcoholic hepatitis is a disease entity with a particular poor prognosis. Any liver disease of unknown cause is suspected as being drug-associated. Every new drug metabolized in the liver has the potential to damage the liver. Primary biliary cirrhosis has seen significant progress due to the identification of new risk factors based on new epidemiological studies. Interface hepatitis has become a prognostic marker as well as a therapeutic target. The treatment of autoimmune hepatitis has progressed significantly due to an individualized approach to immunosuppression.

Available Colors

N/A

Available Sizes

N/A